{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T12:29:11Z","timestamp":1772627351739,"version":"3.50.1"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.pupt.2017.03.017","type":"journal-article","created":{"date-parts":[[2017,4,4]],"date-time":"2017-04-04T16:11:35Z","timestamp":1491322295000},"page":"11-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Response to the article \u201cSorafenib as a potential strategy for refractory pulmonary arterial hypertension\u201d"],"prefix":"10.1016","volume":"45","author":[{"given":"Jason","family":"Weatherald","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Humbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Guignabert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Montani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2017.03.017_bib1","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.pupt.2017.03.009","article-title":"Sorafenib as a potential strategy for refractory pulmonary arterial hypertension","volume":"44","author":"Kimura","year":"2017","journal-title":"Pulm. Pharmacol. Ther."},{"key":"10.1016\/j.pupt.2017.03.017_bib2","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S2213-2600(16)30438-6","article-title":"Clinical phenotypes and outcomes of heritable and sporadic pulmonary veno-occlusive disease: a population-based study","volume":"5","author":"Montani","year":"2017","journal-title":"Lancet Respir. Med."},{"issue":"5","key":"10.1016\/j.pupt.2017.03.017_bib3","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1183\/13993003.00026-2016","article-title":"Pulmonary veno-occlusive disease","volume":"47","author":"Montani","year":"2016","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pupt.2017.03.017_bib4","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1055\/s-0033-1356494","article-title":"Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword?","volume":"34","author":"Godinas","year":"2013","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2017.03.017_bib5","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1161\/CIRCULATIONAHA.112.000765","article-title":"Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study","volume":"127","author":"Hoeper","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.pupt.2017.03.017_bib6","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.healun.2015.05.025","article-title":"Long-term safety and efficacy of imatinib in pulmonary arterial hypertension","volume":"34","author":"Frost","year":"2015","journal-title":"J. Heart Lung Transpl."},{"issue":"3","key":"10.1016\/j.pupt.2017.03.017_bib7","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/clpt.2009.217","article-title":"A dosing\/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension","volume":"87","author":"Gomberg-Maitland","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.pupt.2017.03.017_bib8","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1161\/CIRCULATIONAHA.108.779751","article-title":"Combined tyrosine and serine\/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling","volume":"118","author":"Klein","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.pupt.2017.03.017_bib9","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1152\/physiolgenomics.00169.2007","article-title":"Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension","volume":"33","author":"Moreno-Vinasco","year":"2008","journal-title":"Physiol. Genomics"},{"key":"10.1016\/j.pupt.2017.03.017_bib10","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1161\/CIRCRESAHA.114.303200","article-title":"Sorafenib cardiotoxicity increases mortality after myocardial infarction","volume":"114","author":"Duran","year":"2014","journal-title":"Circ. Res."},{"key":"10.1016\/j.pupt.2017.03.017_bib11","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1172\/JCI200420317","article-title":"Cardiac-specific disruption of the c-raf-1 gene induces cardiac dysfunction and apoptosis","volume":"114","author":"Yamaguchi","year":"2004","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.pupt.2017.03.017_bib12","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1093\/toxsci\/kfu235","article-title":"Downregulation of stanniocalcin 1 is responsible for sorafenib-induced cardiotoxicity","volume":"143","author":"Kawabata","year":"2015","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.pupt.2017.03.017_bib13","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/toxsci\/kfn157","article-title":"Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells","volume":"106","author":"Will","year":"2008","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.pupt.2017.03.017_bib14","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","article-title":"Pulmonary arterial hypertension in patients treated by dasatinib","volume":"125","author":"Montani","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.pupt.2017.03.017_bib15","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1172\/JCI86249","article-title":"Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension","volume":"126","author":"Guignabert","year":"2016","journal-title":"J. Clin. Invest"}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553917301001?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553917301001?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T19:57:55Z","timestamp":1535918275000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553917301001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":15,"alternative-id":["S1094553917301001"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2017.03.017","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Response to the article \u201cSorafenib as a potential strategy for refractory pulmonary arterial hypertension\u201d","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2017.03.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}